Cardinal Point Capital Management ULC Acquires 2,745 Shares of Pfizer Inc. $PFE

Cardinal Point Capital Management ULC raised its holdings in shares of Pfizer Inc. (NYSE:PFE) by 0.9% in the 2nd quarter, Holdings Channel.com reports. The fund owned 312,032 shares of the biopharmaceutical company’s stock after buying an additional 2,745 shares during the period. Cardinal Point Capital Management ULC’s holdings in Pfizer were worth $7,564,000 as of its most recent SEC filing.

Other hedge funds also recently made changes to their positions in the company. GKV Capital Management Co. Inc. bought a new position in shares of Pfizer during the 1st quarter worth approximately $27,000. North Capital Inc. bought a new position in shares of Pfizer during the 1st quarter worth approximately $28,000. Bayforest Capital Ltd bought a new position in shares of Pfizer during the 1st quarter worth approximately $28,000. Harbor Asset Planning Inc. bought a new stake in shares of Pfizer during the 2nd quarter worth approximately $29,000. Finally, Horizon Financial Services LLC bought a new stake in shares of Pfizer during the 1st quarter worth approximately $35,000. 68.36% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

PFE has been the topic of a number of analyst reports. Citigroup upped their price objective on Pfizer from $25.00 to $26.00 and gave the stock a “neutral” rating in a research note on Wednesday, August 6th. Morgan Stanley dropped their price objective on Pfizer from $33.00 to $32.00 and set an “equal weight” rating on the stock in a research note on Friday, October 10th. Weiss Ratings reiterated a “hold (c-)” rating on shares of Pfizer in a research note on Wednesday, October 8th. UBS Group restated a “neutral” rating and issued a $28.00 price target on shares of Pfizer in a research report on Wednesday, October 1st. Finally, Wall Street Zen cut Pfizer from a “buy” rating to a “hold” rating in a research report on Sunday, September 28th. Two equities research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, eleven have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $28.13.

Pfizer Stock Performance

NYSE:PFE opened at $24.68 on Friday. The stock’s 50-day simple moving average is $24.87 and its 200 day simple moving average is $24.15. The firm has a market capitalization of $140.29 billion, a PE ratio of 13.13, a price-to-earnings-growth ratio of 0.82 and a beta of 0.55. The company has a quick ratio of 0.85, a current ratio of 1.16 and a debt-to-equity ratio of 0.65. Pfizer Inc. has a twelve month low of $20.92 and a twelve month high of $29.17.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 EPS for the quarter, beating analysts’ consensus estimates of $0.58 by $0.20. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The firm had revenue of $14.65 billion for the quarter, compared to analyst estimates of $13.43 billion. During the same period last year, the firm posted $0.60 earnings per share. The business’s revenue for the quarter was up 10.3% on a year-over-year basis. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. On average, analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Monday, December 1st. Shareholders of record on Friday, November 7th will be issued a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a yield of 7.0%. The ex-dividend date is Friday, November 7th. Pfizer’s payout ratio is presently 91.49%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.